Battle against time for innovative cancer treatment: an updated cost-effectiveness analysis of pemigatinib in intrahepatic cholangiocarcinoma.
- DOI
- 10.1186/s12962-025-00713-w
- Published
- 2026 Feb 10
- Container
- Cost effectiveness and resource allocation : C/E
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1186/s12962-025-00713-w,
title = {Battle against time for innovative cancer treatment: an updated cost-effectiveness analysis of pemigatinib in intrahepatic cholangiocarcinoma.},
author = {Wang IT and Chen HL and Huang WM and Chiang NJ and Shen LJ and Chueh CH and Tsai YW},
year = {2026},
journal = {Cost effectiveness and resource allocation : C/E},
doi = {10.1186/s12962-025-00713-w},
url = {https://doi.org/10.1186/s12962-025-00713-w}
}RIS
TY - JOUR TI - Battle against time for innovative cancer treatment: an updated cost-effectiveness analysis of pemigatinib in intrahepatic cholangiocarcinoma. AU - Wang IT AU - Chen HL AU - Huang WM AU - Chiang NJ AU - Shen LJ AU - Chueh CH AU - Tsai YW PY - 2026 JO - Cost effectiveness and resource allocation : C/E DO - 10.1186/s12962-025-00713-w UR - https://doi.org/10.1186/s12962-025-00713-w ER -
APA
IT, W., HL, C., WM, H., NJ, C., LJ, S., CH, C., & YW, T. (2026). Battle against time for innovative cancer treatment: an updated cost-effectiveness analysis of pemigatinib in intrahepatic cholangiocarcinoma.. Cost effectiveness and resource allocation : C/E. https://doi.org/10.1186/s12962-025-00713-w
Source records
- pubmed · retrieved 2026-09-26T12:12:14.410Z